Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretrovival therapy

AIDS

Volumn 12, Issue 11, 1998, Pages 1267-1273

  Bouscarat, Fabrice ^a   Levacher, Maryse ^a,b   Landman, Roland ^c   Muffat Joly, Martine ^a   Girard, Pierre Marie ^d   Saimot, Adrien G ^c   Brun Vézinet, Françoise ^c   Sinet, Martine ^a,c,e  

^a INSERM   (France)

^b Department of Pharmacology ^*  (France)

^c BICHAT HOSPITAL   (France)

^d HÔPITAL ROTHSCHILD   (France)

^e Hôpital Cochin ^*  (France)

Author keywords

AIDS; Antiretroviral therapy; CD8+ activation; HIV; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HLA DR ANTIGEN; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; RNA ANALYSIS; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

EID: 0032581692     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00007     Document Type: Article

References (32)

1. Giorgi JV, Detels R: T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort study. Clin Immunol Immunopathol 1989, 52:10-18.
2. Levacher M, Hulstaert F, Tallet S, et al.: The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992, 90:376-382.
3. Giorgi JV, Liu Z, Hultin LE, et al.: Elevated level of CD38+CD8+ cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years follow-up. J Acquir Immune Defic Syndr 1993, 6:904-912.
4. Giorgi JV, Ho HN, Hirji K, et al.: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38-CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis 1994, 170:775-781.
5. Bouscarat F, Levacher-Clergeot M, Dazza MC, et al.: Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996, 12:17-24.
6. Levacher M, Tallet S, Dazza MC, et al.: T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS. Clin Exp Immunol 1990, 81:177-182.
7. Bass HZ, Hardy WD, Mitsuyasu RT, et al.: Eleven lymphoid phenotypic markers in HIV infection: selective changes induced by zidovudine treatment. J Acquir Immune Defic Syndr 1992, 5:890-897.
8. Kestens L, Vanham C, Vereecken C, et al.: Selective increase of activation antigens HLA-DR and CD38 on CD4+CD45RO + T-lymphocytes during HIV-1 infection. Clin Exp Immunol 1994, 95:436-441.
9. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
10. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
11. Centers for Disease Control Working Group: Guidelines for the performance of CD4+ T-cell determinations in persons with human immunodeficiency virus infection. MMWR 1992, 41 (RR-8):1-17.
12. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
13. Brun-Vezinet F, Boucher C, Loveday C, et al.: HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997, 350:983-990.
14. Mellors J, Rinaldo Jr CR, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
15. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426-431.
16. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD: Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
17. Liu Z, Hultin LE, Cumberland WG, et al.: Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 1996, 26:1-7.
18. Mocroft A, Bofill M, Medina E, et al.: CD8+, CD38 + lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:158-162.
19. Cohen OJ, Pantaleo G, Holodniy M, et al.: Decreased human immunodeficiency virus type 1 plasma viremia during anti-retroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA 1995, 92:6017-6021.
20. Lafeuillade A, Tamalet C, Poggi C, Pellegrino P, Tourres C, Izopet J: Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes. AIDS 1997, 11:67-72.
21. Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O: Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma. J Infect Dis 1996, 174:404-407.
22. Cavert W, Notermans DW, Staskus K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
23. Levacher M, Bouscarat F, Chau F, et al.: Evolution of CD4 and CD8 cytokine secreting lymphocytes in HIV infected patients treated with stavudine+didanosine+ritonavir. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 123].
24. Cohen OJ, Pantaleo G, Lam GK, Fauci AS: Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin Immunopathol 1997, 18:305-322.
25. Cohen C: Stubborn HIV reservoirs vulnerable to new treatments. Science 1997, 276:898-899.
26. Ho HN, Hultin LE, Mitsuyasu RT, et al.: Circulating HIV-specific CD8+ cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993, 150:3070-3079.
27. Fiorentino S, Dalod M, Olive D, Guillet JG, Gomard E: Predominant involvement of CD8+CD28-lymphocytes in human immunodeficiency virus-specific cytotoxic activity. J Virol 1996, 70:2022-2026.
28. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency type 1 syndrome. J Virol 1994, 68:4650-4655.
29. Harrer T, Harrer H, Kalams SA, et al.: Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol 1996, 156:2616-2623.
30. Ferbas J, Daar ES, Crovit-Ferbas K, et al.: Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J Virol 1996, 70:7285-7289.
31. Pantaleo C, Fauci AS: Tracking HIV during disease progression. Curr Opin Immunol 1994, 6:600-604.
32. Koup RA: Virus escape from CTL recognition. J Exp Med 1994, 180:779-782.